Skip to main content
OICR News / Tag

Propellon Therapeutics

Browse news tagged Propellon Therapeutics.

Browse all news

Filters

Discover the latest news and insightsDiscover the latest news and insights

Filter by pillar All
Filter by format
More stories

Tagged stories

Commercialization

FACIT Announces Investment in Propellon Therapeutics

Seed financing of CAD$3.0M positions first-in-class WDR5 cancer therapy for clinical development TORONTO, March 22, 2017 /CNW/ - FACIT announced a seed stage investment in Propellon Therapeutics (the "Company" or "Propellon"), a start-up created by…
Article
Commercialization

Propellon Therapeutics to Accelerate WDR5 Inhibitor Development for Cancers

FACIT forms biotechnology company for OICR-discovered first-in-class epigenetic modifiers TORONTO, ON (June 23, 2016) – FACIT has announced the creation of a new Ontario biotechnology company, Propellon Therapeutics Inc. (“Propellon” or “the Company”), to manage…
Article
Newsletter signup

Cancer solved together — in your inbox

The latest findings, funding, and partnerships from Ontario’s cancer research institute. Briefings and deeper dives.

Subscribe